Cargando…

Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India

BACKGROUND: Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear. METHODS: We used a simulation model of HIV testing and trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Venkatesh, Kartik K., Becker, Jessica E., Kumarasamy, Nagalingeswaran, Nakamura, Yoriko M., Mayer, Kenneth H., Losina, Elena, Swaminathan, Soumya, Flanigan, Timothy P., Walensky, Rochelle P., Freedberg, Kenneth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669338/
https://www.ncbi.nlm.nih.gov/pubmed/23741348
http://dx.doi.org/10.1371/journal.pone.0064604
_version_ 1782271736337661952
author Venkatesh, Kartik K.
Becker, Jessica E.
Kumarasamy, Nagalingeswaran
Nakamura, Yoriko M.
Mayer, Kenneth H.
Losina, Elena
Swaminathan, Soumya
Flanigan, Timothy P.
Walensky, Rochelle P.
Freedberg, Kenneth A.
author_facet Venkatesh, Kartik K.
Becker, Jessica E.
Kumarasamy, Nagalingeswaran
Nakamura, Yoriko M.
Mayer, Kenneth H.
Losina, Elena
Swaminathan, Soumya
Flanigan, Timothy P.
Walensky, Rochelle P.
Freedberg, Kenneth A.
author_sort Venkatesh, Kartik K.
collection PubMed
description BACKGROUND: Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear. METHODS: We used a simulation model of HIV testing and treatment to examine alternative HIV screening strategies: 1) current practice, 2) one-time, 3) every five years, and 4) annually; and we applied these strategies to three population scenarios: 1) the general Indian population (“national population”), i.e. base case (HIV prevalence 0.29%; incidence 0.032/100 person-years [PY]); 2) high-prevalence districts (HIV prevalence 0.8%; incidence 0.088/100 PY), and 3) high-risk groups (HIV prevalence 5.0%; incidence 0.552/100 PY). Cohort characteristics reflected Indians reporting for HIV testing, with a median age of 35 years, 66% men, and a mean CD4 count of 305 cells/µl. The cost of a rapid HIV test was $3.33. Outcomes included life expectancy, HIV-related direct medical costs, incremental cost-effectiveness ratios (ICERs), and secondary transmission benefits. The threshold for “cost-effective” was defined as 3x the annual per capita GDP of India ($3,900/year of life saved [YLS]), or for “very cost-effective” was <1x the annual per capita GDP ($1,300/YLS). RESULTS: Compared to current practice, one-time screening was very cost-effective in the national population (ICER: $1,100/YLS), high-prevalence districts (ICER: $800/YLS), and high-risk groups (ICER: $800/YLS). Screening every five years in the national population (ICER: $1,900/YLS) and annual screening in high-prevalence districts (ICER: $1,900/YLS) and high-risk groups (ICER: $1,800/YLS) were also cost-effective. Results were most sensitive to costs of care and linkage-to-care. CONCLUSIONS: In India, voluntary HIV screening of the national population every five years offers substantial clinical benefit and is cost-effective. Annual screening is cost-effective among high-risk groups and in high-prevalence districts nationally. Routine HIV screening in India should be implemented.
format Online
Article
Text
id pubmed-3669338
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36693382013-06-05 Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India Venkatesh, Kartik K. Becker, Jessica E. Kumarasamy, Nagalingeswaran Nakamura, Yoriko M. Mayer, Kenneth H. Losina, Elena Swaminathan, Soumya Flanigan, Timothy P. Walensky, Rochelle P. Freedberg, Kenneth A. PLoS One Research Article BACKGROUND: Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear. METHODS: We used a simulation model of HIV testing and treatment to examine alternative HIV screening strategies: 1) current practice, 2) one-time, 3) every five years, and 4) annually; and we applied these strategies to three population scenarios: 1) the general Indian population (“national population”), i.e. base case (HIV prevalence 0.29%; incidence 0.032/100 person-years [PY]); 2) high-prevalence districts (HIV prevalence 0.8%; incidence 0.088/100 PY), and 3) high-risk groups (HIV prevalence 5.0%; incidence 0.552/100 PY). Cohort characteristics reflected Indians reporting for HIV testing, with a median age of 35 years, 66% men, and a mean CD4 count of 305 cells/µl. The cost of a rapid HIV test was $3.33. Outcomes included life expectancy, HIV-related direct medical costs, incremental cost-effectiveness ratios (ICERs), and secondary transmission benefits. The threshold for “cost-effective” was defined as 3x the annual per capita GDP of India ($3,900/year of life saved [YLS]), or for “very cost-effective” was <1x the annual per capita GDP ($1,300/YLS). RESULTS: Compared to current practice, one-time screening was very cost-effective in the national population (ICER: $1,100/YLS), high-prevalence districts (ICER: $800/YLS), and high-risk groups (ICER: $800/YLS). Screening every five years in the national population (ICER: $1,900/YLS) and annual screening in high-prevalence districts (ICER: $1,900/YLS) and high-risk groups (ICER: $1,800/YLS) were also cost-effective. Results were most sensitive to costs of care and linkage-to-care. CONCLUSIONS: In India, voluntary HIV screening of the national population every five years offers substantial clinical benefit and is cost-effective. Annual screening is cost-effective among high-risk groups and in high-prevalence districts nationally. Routine HIV screening in India should be implemented. Public Library of Science 2013-05-31 /pmc/articles/PMC3669338/ /pubmed/23741348 http://dx.doi.org/10.1371/journal.pone.0064604 Text en © 2013 Venkatesh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Venkatesh, Kartik K.
Becker, Jessica E.
Kumarasamy, Nagalingeswaran
Nakamura, Yoriko M.
Mayer, Kenneth H.
Losina, Elena
Swaminathan, Soumya
Flanigan, Timothy P.
Walensky, Rochelle P.
Freedberg, Kenneth A.
Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title_full Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title_fullStr Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title_full_unstemmed Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title_short Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India
title_sort clinical impact and cost-effectiveness of expanded voluntary hiv testing in india
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669338/
https://www.ncbi.nlm.nih.gov/pubmed/23741348
http://dx.doi.org/10.1371/journal.pone.0064604
work_keys_str_mv AT venkateshkartikk clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT beckerjessicae clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT kumarasamynagalingeswaran clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT nakamurayorikom clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT mayerkennethh clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT losinaelena clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT swaminathansoumya clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT flanigantimothyp clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT walenskyrochellep clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia
AT freedbergkennetha clinicalimpactandcosteffectivenessofexpandedvoluntaryhivtestinginindia